Biocon Rating: Hold – Vaccines to complement biosimilar portfolio
Biocon Rating: Hold – Vaccines to complement biosimilar portfolio
Deal with SILS could add NPV of `21/share to TP; better biosimilar execution remains key; ‘Hold’ retained
No related posts.
[instagram-feed]